References
- 1. D. Sahu and A. Rana, Formulation development of Quetiapine Fumarate SR matrix tablets, Der Pharm. Sin. 1 (2010) 48-57.
- 2. S. Cheer and A. Wagstaff, Quetiapine. A review of its use in the management of schizophrenia, CNS Drugs 18 (2004) 173-199; DOI: 10.2165/00023210-200418030-00004.10.2165/00023210-200418030-00004
- 3. G. Garbacz, A. Kandzi, M. Koziolek, J. Mazgalski and W. Weitschies, Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions, AAPS PharmSciTech 15 (2014) 230-236; DOI: 10.1208/s12249-013-0050-2.10.1208/s12249-013-0050-2
- 4. S. Chopra, G. V. Patil and S. K. Motwani, Release modulating hydrophilic matrix systems of losartan potassium: Optimization of formulation using statistical experimental design, Eur. J. Pharm. Biopharm. 66 (2007) 73-82; DOI: 10.1016/j.ejpb.2006.09.001.10.1016/j.ejpb.2006.09.001
- 5. P. W. S. Heng, L. W. Chan, M. G. Easterbrook and X. Li, Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets, J. Control. Release 76 (2001) 39-49; DOI: 10.1016/S0168-3659(01)00410-2.10.1016/S0168-3659(01)00410-2
- 6. S. Tiwari and A. R. Rajabi-Siahboomi, Modulation of drug release from hydrophilic matrices, Pharm. Tech. Eur. 20 (2008) 24-32.
- 7. I. Tomuta and S. E. Leucuta, The influence of formulation factors on the kinetic release of metoprolol tartrate from Prolong release coated minitablets, Drug Dev. Ind. Pharm. 33 (2007) 1070-1077; DOI: 10.1080/03639040601180002.10.1080/03639040601180002
- 8. R. Asija, S. Asija and M. Carpenter, Design of oral sustain release drug delivery of quetiapine fumarate, J. Drug Discov. Ther. 2 (2014) 7-11.
- 9. S. Tiwari and A. Rajabi-Siahboomi, Applications of complementary polymers in HPMC hydrophilic extended release matrices, Drug Deliv. Technol. 9 (2009) 20-27.
- 10. J. Djuriš, D. Medarević, M. Krstić, I. Vasiljević, I. Mašić and S. Ibrić, Design space approach in optimization of fluid bed granulation and tablets compression process, Sci. World J. (2012) 1-10; DOI: 10.1100/2012/185085.10.1100/2012/185085
- 11. F. Rose, J. E. Wern, P. T. Ingvarsson, M. Van De, P. Andersen, F. Follmann and C. Foged, Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach, J. Control. Release 28 (2015) 48-57; DOI: 10.1016/j.jconrel.2015.05.004.10.1016/j.jconrel.2015.05.004
- 12. L. X. Yu, Pharmaceutical quality by design: Product and process development, understanding and control, Pharm. Res. 25 (2008) 781-791; DOI: 10.1007/s11095-007-9511-1.10.1007/s11095-007-9511-1
- 13. A. L. Vonica-Gligor, I. Tomuţă and S. E. Leucuţa, Piecewise function parameters as responses of the design of experiment in the development of a pulsatile release chronopharmaceutical system, Acta Pol. Pharm. 66 (2016) 173-189; DOI: 10.1515/acph-2016-0025.10.1515/acph-2016-0025
- 14. S. Dash, P. N. Murthy, L. Nath and P. Chowdhury, Kinetic modeling on drug release from controlled drug delivery systems, Acta Pol. Pharm. 67 (2010) 217-223; DOI: 10.1016/S0928-0987(01)00095-1.10.1016/S0928-0987(01)00095-1
- 15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2009. ICH harmonised tripartite guideline: Pharmaceutical development Q8(R2); Retrieved from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
- 16. N. Charoo, A. Shamsher, A. Zidan and Z. Rahman, Quality by design approach for formulation development : A case study of dispersible tablets, Int. J. Pharm. 423 (2012) 167-178; DOI: 10.1016/j. ijpharm.2011.12.024.
- 17. European Pharmacopeia 8.8. Online Edition 2016.
- 18. S. Shahi, D. Magar, T. Ingale and H. Mene, QbD approach in formulation and evaluation of duloxetine Hcl bilayer buccal tablets, Lit. J. Pharm. Drug Deliv. Technol. 01 (2015) 29-36; DOI: 10.15272/ ljpddt.v1i1.8.
- 19. MODDE 11.0. Software for Design of Experiments: User’s Guide and Tutorial, Umetrics Academy, Umea 2015.
- 20. S. Iurian, I. Tomuta, C. Bogdan, L. Rus, T. Tokes, M. Achim, M. Moldovan and S. Leucuta, Defining the design space for freeze-dried orodispersible tablets with meloxicam, Drug Dev. Ind. Pharm. 9045 (2016); DOI: 10.1080/03639045.2016.1188108.10.1080/03639045.2016.1188108
- 21. J. Wagner, Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules, J. Pharm. Sci. 58 (1969) 1253-1257; DOI: 10.1002/jps.2600581021. 10.1002/jps.2600581021
- 22. I. Prasacu, C. Mircioiu, R. Sandulovici and F. Enache, Release of metoprolol from solid dosage forms. Choice and validation of theoretical model, Farmacia 57 (2009) 89-100.
- 23. T. Higuchi, Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J. Pharm. Sci. 52 (1963) 1145-1149.10.1002/jps.2600521210
- 24. A. W. Hixson and J. H. Crowell, Dependence of reaction velocity upon surface and agitation, Ind. Eng. Chem. 23 (1931) 923-931.10.1021/ie50260a018
- 25. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. Peppas, Mechanisms of solute release from porous hydrophilic polymers, Int. J. Pharm. 15 (1983) 25-35; DOI: 10.1016/0378-5173(83)90064-9.10.1016/0378-5173(83)90064-9
- 26. L. Eriksson, E. Johansson, N. Kettaneh-Wold, C. Wikstrom and S. Wold, Design of Experiments, Principles and Applications (3rd ed.), Umetrics Academy, Umea 2008.
- 27. A. Porfire, I. Tomuta, D. Muntean, L. Luca, E. Licarete, M. C. Alupei, M. Achim, L. Vlase and M. Banciu, Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells, J. Liposome Res. (2014) 1-9; DOI: 10.3109/08982104.2014.987787.10.3109/08982104.2014.987787
- 28. M. Levina and A. R. Rajabi-Siahboomi, The influence of excipients on drug release from hydroxypropyl methylcellulose matrices, J. Pharm. Sci. 93 (2004) 2746-2754; DOI: 10.1002/jps.20181.10.1002/jps.20181
- 29. R. Rowe, P. Sheskey and M. Quinn, Handbook of Pharmaceutical Excipients (6th ed.), London: Pharmaceutical Press; DOI: 10.1016/S0168-3659(01)00243-7.10.1016/S0168-3659(01)00243-7
- 30. C. Lui, Sustained Release with High and Low Viscosity HPMC, U.S. Pat. 5009895, 23 Apr 1991.
- 31. J. Manjusha, G. Ganesh Vinayak and M. Satish Ramanlal, Sustained Release Formulation of Alprazolam, WO2007010369 A2, 25 Jan 2007.
- 32. V. P. Shah, Y. Tsong, P. Sathe and J.-P. Liu, In vitro dissolution profile comparison - statistics and analysis of the similarity factor, f2 15 (1998) 889-896; DOI: 10.1023/A:1011976615750.10.1023/A:1011976615750
- 33. P. Kulinowski, K. Woyna-Orlewicz, J. Obrał, G. M. Rappen, D. Haznar-Garbacz, W. P. Węglarz, R. Jachowicz, G. Wyszogrodzka, J. Klaja and P. P. Dorozyński, Multimodal approach to characterization of hydrophilic matrices manufactured by wet and dry granulation or direct compression methods, Int. J. Pharm. 499 (2016) 263-270; DOI: 10.1016/j.ijpharm.2015.12.067.10.1016/j.ijpharm.2015.12.06726752087
- 34. P. Kulinowski, K. Woyna-Orlewicz, G. M. Rappen, D. Haznar-Garbacz, W. P. Weglarz and P. P. Dorozynski, An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - Case study of multimodal characterization of quetiapine fumarate tablets, Int. J. Pharm. 484 (2015) 235-245; DOI: 10.1016/j.ijpharm.2015.02.040. 10.1016/j.ijpharm.2015.02.04025701626